Weed (BUDZ) Liabilities and Shareholders Equity (2010 - 2026)
Weed (BUDZ) posted quarterly Liabilities and Shareholders Equity of $515713.0 for Q1 2026, down 10.33% year-over-year from $575128.0 in Q1 2025, and down 7.89% quarter-over-quarter from $559906.0 in Q4 2025.
Weed (BUDZ) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Weed's Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $515713.0 for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 10.33% year-over-year to $515713.0; the TTM figure through Mar 2026 stood at $2.2 million (down 14.2% YoY), while the FY2025 annual figure was $559906.0, down 24.17% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $515713.0, down from $559906.0 in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $2.8 million in Q2 2022, with the low at $515713.0 in Q1 2026.
- The 5-year median for Liabilities and Shareholders Equity is $738366.0 (2024), against an average of $1.1 million.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 50.73% in 2022, then plunged 53.89% in 2024.
- Weed's Liabilities and Shareholders Equity stood at $1.6 million in 2022, then slumped by 44.67% to $904062.0 in 2023, then retreated by 18.33% to $738366.0 in 2024, then dropped by 24.17% to $559906.0 in 2025, then decreased by 7.89% to $515713.0 in 2026.
- Business Quant data shows BUDZ's Liabilities and Shareholders Equity at $515713.0 in Q1 2026, $559906.0 in Q4 2025, and $532267.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 6.18 Bn |
| 10 | Weed | 2.88 Mn | 2.88 Mn | - | 504,025.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 515,713.00 |
| Dec 31, 2025 | 559,906.00 |
| Sep 30, 2025 | 532,267.00 |
| Jun 30, 2025 | 548,906.00 |
| Mar 31, 2025 | 575,128.00 |
| Dec 31, 2024 | 738,366.00 |
| Sep 30, 2024 | 596,818.00 |
| Jun 30, 2024 | 603,296.00 |
| Mar 31, 2024 | 703,807.00 |
| Dec 31, 2023 | 904,062.00 |
| Sep 30, 2023 | 1.28 Mn |
| Jun 30, 2023 | 1.31 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | 1.63 Mn |
| Sep 30, 2022 | 2.44 Mn |
| Jun 30, 2022 | 2.77 Mn |
| Mar 31, 2022 | 1.94 Mn |
| Dec 31, 2021 | 1.96 Mn |
| Sep 30, 2021 | 1.81 Mn |
| Jun 30, 2021 | 1.84 Mn |